Marinus Pharma (MRNS) Tops Q3 EPS by 20c; Reports Cash and Cash Equivalents of $145.1M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
November 9, 2021 7:00 AM ESTEuropean Medicines Agency has accepted the Marketing Authorization Application for ganaxolone in CDKL5 deficiency disorder for review under accelerated assessment European Commission granted orphan drug designation to ganaxolone in tuberous sclerosis complex; Phase 3 TrustTSC program on track to initiate patient enrollment Q1 2022 Continued improvements in site activation for Phase 3 RAISE trial in refractory status epilepticus Nine abstracts accepted for poster session presentations and virtual analyst and investor event planned for December 6 at American Epilepsy Society 2021 Annual Meeting Received additional $30 million of funding under the existing Oaktree Capital Management, L.P. credit... More
